Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis
Verra M. Ngwa, Yoonha Hwang, Wenqiang Song, Deanna N. Edwards, Jin Chen
This study shows targeting mTORC2 in lung squamous cell carcinoma enhances anti-tumor immunity via the PSGL-1-VISTA axis by altering the tumor microenvironment and immune cell activation.
Cancer Gene Therapy · Jul 10, 2025Peer-reviewedCancer Biology